Actively Recruiting
Phase 2 Study of Toripalimab and JS004 with Etoposide and Platinum Chemotherapy as Neoadjuvant Treatment for Limited-Stage Small Cell Lung Cancer
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2024-05-29
30
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new treatment approach for people with limited-stage small cell lung cancer SCLC. The trial focuses on combining two antibodies, toripalimab and JS004, with standard chemotherapy drugs etoposide and platinum. This combination aims to improve the rate of complete pathological response, which is currently low with existing treatments. JS004 targets a protein called BTLA that helps cancer cells avoid the immune system, and combining it with a PD-1 antibody like toripalimab has shown promise in solid tumors. In this phase 2 trial, 30 patients will receive four cycles of the combined treatment before surgery. Patients whose tumors can be surgically removed after the neoadjuvant therapy will undergo surgery, followed by two additional cycles of the combination therapy. Afterward, participants will receive maintenance treatment with toripalimab and JS004 until their disease progresses. Participants will be monitored for up to 30 months to assess the complete response of their cancer to the therapy. Researchers will also evaluate other outcomes including tumor response, treatment side effects, event-free survival, overall survival, and quality of life measures up to 60 months. The study includes regular imaging, lab tests, and health assessments to monitor safety and effectiveness throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Research Team
P
Peng Zhang, PhD
T
Tao Ge, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here